0.8542USD+3.13%Mkt Cap: 13.46M USDP/E: —Last update: 2026-06-01
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora,…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap13.46M USD
Enterprise Value11.15M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.56M USD
Revenue/Share—
Last Price0.8542 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.50
PEG—
EV/EBITDA-0.50
EV/Revenue—
P/S—
P/B-11.35
EPS (TTM)-1.31
EPS (Forward)-1.63
52W Range
0.46106% of range7.200
52W High7.200 USD
52W Low0.4610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE445.14%
ROA-217.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.18M USD
CapEx (TTM)28.00K USD
FCF Margin—
FCF Yield—
Net Debt-1.46M USD
Net Debt/EBITDA0.07
Balance Sheet
Debt/Equity-1.46
Current Ratio1.61
Quick Ratio1.54
Book Value/Sh-0.0720 USD
Cash/Share0.5290 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)10.33 USD
Target Range6.000 USD – 15.00 USD
# Analysts3
Ownership
Shares Out.15.80M
Float8.94M
Insiders14.35%
Institutions36.05%
Short Interest
Short Ratio0.9d
Short % Float2.80%
Short % Out.0.86%
Shares Short136.41K
Short (prev mo.)372.16K
Technical
SMA 500.6279 (+36.0%)
SMA 2002.518 (-66.1%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)139.08K
Avg Vol (10d)136.83K
Technical Indicators
RSI (14)65.2
MACD0.0373
MACD Signal0.0111
MACD Hist.+0.0263
BB Upper0.8200 USD
BB Middle0.6626 USD
BB Lower0.5052 USD
BB Width47.51%
ATR (14)0.0764 USD
Vol Ratio (20d)2.33x